Berard J L, Velez R L, Freeman R B, Tsunoda S M
Department of Pharmacy Practice, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115-5000, USA.
Pharmacotherapy. 1999 Oct;19(10):1127-37. doi: 10.1592/phco.19.15.1127.30582.
Daclizumab and basiliximab, engineered human IgG monoclonal antibodies to the interleukin-2 (IL-2) receptor alpha-subunit, were approved to prevent acute rejection after renal transplantation. Daclizumab was studied in adult and pediatric renal allograft recipients, liver allograft recipients, and calcineurin-sparing protocols in renal transplant recipients. Basiliximab was studied in renal allograft recipients and subgroups of recipients of living-related and cadaveric transplants, and in patients with diabetes mellitus. Both agents reduced acute rejection and were associated with few adverse effects. However, information regarding their long-term effects on infection, malignancy, chronic rejection, and patient survival must be available before a final decision is made regarding their proper administration. We propose that a likely role the drugs will play in the field of solid organ transplantation is in new protocols that allow sparing of other more toxic immunosuppressive agents.
达利珠单抗和巴利昔单抗是针对白细胞介素-2（IL-2）受体α亚基设计的人源化IgG单克隆抗体，已被批准用于预防肾移植后的急性排斥反应。达利珠单抗在成人和儿童肾移植受者、肝移植受者以及肾移植受者的无钙调神经磷酸酶方案中进行了研究。巴利昔单抗在肾移植受者以及亲属活体和尸体移植受者亚组以及糖尿病患者中进行了研究。两种药物均能降低急性排斥反应，且不良反应较少。然而，在就其合理用药做出最终决定之前，必须掌握有关它们对感染、恶性肿瘤、慢性排斥反应和患者生存率的长期影响的信息。我们认为，这些药物在实体器官移植领域可能发挥的作用是在新的方案中，使其他毒性更强的免疫抑制剂得以减量使用。
